• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs.

作者信息

Messori A, Longo G, Morfini M, Cinotti S, Filimberti E, Giustarini G, Rossi Ferrini P

机构信息

Haemophilia Centre, University of Florence, Italy.

出版信息

Eur J Clin Pharmacol. 1988;35(6):663-8. doi: 10.1007/BF00637604.

DOI:10.1007/BF00637604
PMID:3148473
Abstract

The pharmacokinetics of Factor VIII was evaluated by mathematical modeling in a large-scale study in 62 haemophilia-A subjects, in whom 137 plasma Factor VIII-time curves were measured during single dose (n = 87) and repeated-dose (n = 47) treatments for prophylaxis or minor bleeding episodes. The pharmacokinetic parameters [mean (SD)] estimated from single-dose curves were: clearance 3.85 ml.h-1.kg-1, volume of distribution 58.2 ml.kg-1, mean residence time 15.9 h. Parameters calculated from repeated-dose curves were: clearance 3.93 ml.h-1.kg-1, volume of distribution 61.8 ml.kg-1, and half-life 12.2 h. In patients with mild haemophilia, pharmaco-statistical analysis revealed that the endogenous synthesis of Factor VIII was constant and was not influenced by the administration of exogenous Factor VIII. The coefficient of variation for intra-individual variability of Factor VIII kinetics (estimated according to the Standard Two-Stage method) was 20.7% in single-dose curves and 23.2% in repeated-dose curves.

摘要

相似文献

1
Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs.
Eur J Clin Pharmacol. 1988;35(6):663-8. doi: 10.1007/BF00637604.
2
A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.一种用于估计甲型血友病患者凝血因子 VIII 个体药代动力学参数的有限采样策略。
Ther Drug Monit. 2007 Feb;29(1):20-6. doi: 10.1097/FTD.0b013e3180311384.
3
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.儿童和成人血浆游离型和白蛋白结合型重组因子 VIII 的比较药代动力学:采血方案对观察到的与年龄相关差异的影响及其对剂量调整的意义。
J Thromb Haemost. 2010 Apr;8(4):730-6. doi: 10.1111/j.1538-7836.2010.03757.x.
4
BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.BAY 94-9027,一种聚乙二醇化重组因子 VIII,在严重血友病 A 患者中表现出延长的半衰期和更高的曲线下面积:来自临床研究的综合药代动力学评估。
Haemophilia. 2018 Sep;24(5):733-740. doi: 10.1111/hae.13561. Epub 2018 Jul 2.
5
In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.体内因子VIII和因子IX的恢复:临床环境中的个体内和个体间差异
Haemophilia. 2007 Jan;13(1):2-8. doi: 10.1111/j.1365-2516.2006.01401.x.
6
Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa.凝血因子VIII活性药代动力学的阐明:对接受莫罗凝血因子α治疗的甲型血友病患者的汇总群体分析。
Clin Pharmacol Ther. 2017 Dec;102(6):977-988. doi: 10.1002/cpt.716. Epub 2017 May 30.
7
Comparative study of four different pharmacokinetic computer programs: case study of a factor VIII preparation.四种不同药代动力学计算机程序的比较研究:以一种凝血因子 VIII 制剂为例
Eur J Clin Pharmacol. 1997;52(1):59-64. doi: 10.1007/s002280050249.
8
Clinical pharmacokinetics of factor VIII in patients with classic haemophilia.
Clin Pharmacokinet. 1987 Dec;13(6):365-80. doi: 10.2165/00003088-198713060-00002.
9
Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight.人群药代动力学研究:VIII 因子重组体的药代动力学与年龄和体重的关系。
Blood. 2012 Jan 12;119(2):612-8. doi: 10.1182/blood-2011-07-360594. Epub 2011 Oct 31.
10
Adjusted dose continuous infusion of factor VIII in patients with haemophilia A.血友病A患者中凝血因子VIII的调整剂量持续输注
Br J Haematol. 1992 Dec;82(4):729-34. doi: 10.1111/j.1365-2141.1992.tb06951.x.

引用本文的文献

1
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia.血友病中凝血因子浓缩物和去氨加压素的群体药代动力学。
Clin Pharmacokinet. 2021 Jan;60(1):1-16. doi: 10.1007/s40262-020-00936-5.
2
Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner.去氨加压素的给药并未以具有临床意义的方式改善凝血因子VIII浓缩剂的药代动力学。
J Clin Transl Res. 2018 Feb 21;3(Suppl 2):351-357. eCollection 2018 Jul 30.
3
The History of Clotting Factor Concentrates Pharmacokinetics.

本文引用的文献

1
THE IN VIVO LONGEVITY OF ANTIHAEMOPHILIC FACTOR (FACTOR VIII).抗血友病因子(因子VIII)的体内寿命
Br J Haematol. 1964 Apr;10:225-37. doi: 10.1111/j.1365-2141.1964.tb00697.x.
2
Some suggestions for measuring predictive performance.一些关于衡量预测性能的建议。
J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12. doi: 10.1007/BF01060893.
3
Successive factor VIII doses for a haemophiliac undergoing major surgery calculated on a micro-computer.利用微型计算机为接受大手术的血友病患者计算连续的因子VIII剂量。
凝血因子浓缩物药代动力学的历史
J Clin Med. 2017 Mar 20;6(3):35. doi: 10.3390/jcm6030035.
4
Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.VIII 因子的异速生长与新一代治疗性蛋白的信息缩放。
J Pharm Sci. 2013 Jul;102(7):2380-94. doi: 10.1002/jps.23566. Epub 2013 Apr 25.
Thromb Haemost. 1982 Feb 26;47(1):66-8.
4
Calculating the dose of factor VIII in the management of haemophilia.
Br J Haematol. 1981 Jun;48(2):351-4.
5
Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.群体药代动力学参数估计方法的评价。III. 单指数模型:常规临床药代动力学数据
J Pharmacokinet Biopharm. 1983 Jun;11(3):303-19. doi: 10.1007/BF01061870.
6
A calculator program for individualizing factor VIII dosage.用于个体化凝血因子VIII剂量的计算器程序。
Drug Intell Clin Pharm. 1984 Sep;18(9):726-30. doi: 10.1177/106002808401800911.
7
A weighted least-squares approach for fitting to kinetic models the plasma concentration data of phenytoin and Factor VIII.一种用于将苯妥英和凝血因子 VIII 的血浆浓度数据拟合到动力学模型的加权最小二乘法。
Farmaco Prat. 1984 Jul;39(7):211-21.
8
Individualization of Factor VIII dosage.凝血因子 VIII 剂量的个体化
J Clin Hosp Pharm. 1984 Jun;9(2):95-103. doi: 10.1111/j.1365-2710.1984.tb01065.x.
9
Surgery in hemophilia and related disorders. A prospective study of 100 consecutive procedures.血友病及相关疾病的外科手术。对100例连续手术的前瞻性研究。
Medicine (Baltimore). 1986 Jan;65(1):34-45. doi: 10.1097/00005792-198601000-00002.
10
A calculator program for clinical application of the Bayesian method of predicting plasma drug levels.
Comput Programs Biomed. 1985;19(2-3):167-77. doi: 10.1016/0010-468x(85)90008-x.